Empower gene table with cancer risk recommendations

Select the Empower gene panel of interest from the “Filter by Panel” dropdown menu, then hit Apply to view the included genes (listed in alphabetical order). Search for a particular gene of interest in the “Search by Gene” box. Hit the Reset button between new searches.

The information shown is based on the latest publication data available, and a PubMed identification (PMID) number is listed for each risk association. We will update this table regularly as new data becomes available.

For desktop viewing: hover your mouse over a colored dot to view how a gene mutation confers risk for each of 12+ hereditary cancer types within a pop-up box. To scroll for more information within a pop-up box, pause your mouse on the colored dot, then shift horizontally over to the pop-up box.

Download Table

Filter Screenings

Gene	Breast	Ovarian	Endometrial	Colorectal	Melanoma	Pancreatic	Gastric	Prostate	Renal	Other	Panels	Resources
ABRAXAS1	Possibly increased										Custom Order	PMID: 22357538
ACD										Possibly increased: squamous cell carcinoma of head and neck or anogenital region, acute myelogenous leukemia (AML)	Custom Order	PMID: 25205116
AIP				Increased in mutation carriers who also have a diagnosis of acromegaly						Pituitary adenoma: Increased PMID: 23371967, 22720333	Comprehensive (81 genes)	PMID: 22720333, 23371967
AKT1	Possibly increased		Possibly increased	Possibly increased	Possibly increased				Possibly increased	Possibly increased: thyroid cancer	Custom Order	PMID: 23246288
ALK										Neuroblastic tumor: Increased PMID: 28674118, 20301782	Comprehensive (81 genes)	PMID: 28674118, 20301782
ANKRD26										Possibly increased: Myeloid malignancies including myelodysplastic syndrome, acute myelogenous leukemia, and chronic myelogenous leukemia	Custom Order	PMID: 29927566; 29222283
AP2S1										Possibly increased: Hyperparathyroidism	Custom Order	PMID: 26082470; 23222959; 24731014
APC				Without removal of colon for FAP: up to 100% Without removal of colon for AFAP: up to 70% Rectal cancer risk after removal of colon for FAP: 10-30%			0.1-7.1%			Thyroid: <2% Duodenal: 4-12% PMID: 28185118, 26819281 Brain/CNS: Increased PMID: 17238184, 18612695 Hepatoblastoma: 1-2% PMID: 16317745, 18612695, NCCN CRC	Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2023 PMID: 24213224, 28185118, 26819281
APC (p.I1307K)				5-10%		Periampullary: <1-10%					Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022
APC GAPPS				Unknown (insufficient data)			12-25%				Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2023
ATM	Female: 20-30%* *Carriers of the c.7271T>G variant have a higher risk for breast cancer, estimated to be as high as 69% by age 70	2-3%		5-10% (limited evidence)		~5-10%		Possibly increased			GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024 PMID 36827971, 26662178, 37239385
ATR								Possibly increased		Possibly increased: Oropharyngeal	Custom Order	PMID: 22341969; 17431037; 27433846; 29915322
AXIN2				Unknown; not enough data to define Increased risk for polyposis (many polyps)							Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 21416598 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022
BAP1					Cutaneous melanoma (skin): ~15%; uveal melanoma (eye): ~30%				9-10%	Malignant mesothelioma: 22% PMID: 26096145	Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 26096145, 28793149, 27748099
BARD1	Female: 17-30%										Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024
BLM (biallelic)	Increased			Increased			Increased		Increased: Wilms tumor	Leukemia, lymphoma, small intestine, esophagus, Oropharyngeal, cervical, skin (non-melanoma), lung	Custom Order	PMID: 20301572; 30055079; 34650095
BLM (monoallelic)				Possibly increased							Custom Order	PMID: 20301572; 12242432; 26358404; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V2.2023
BMPR1A				40-50%			Up to 21% if multiple polyps present			Small bowel: Rare, currently undefined PMID: 9429144	Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022
BRCA1	Female: >60% Male: 0.2- 1.2%	39-58%	Possibly slightly increased (limited data)					7-26%			BRCA1 and BRCA2 (2 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 PMID 36827971, 37239385
BRCA2	Female: >60% Male: 1.8- 7.1%	13-29%	Possibly slightly increased (limited data)		Increased	5-10%		19-61%			BRCA1 and BRCA2 (2 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 PMID 36827971, 37239385
BRIP1	Female: Possibly increased (not enough data to define risk)	5-15%									GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.1.2023
BUB1B (biallelic)									Possibly increased: Wilms tumor (nephroblastoma)	Possibly increased: rhabdomyosarcoma, leukemia	Custom Order	PMID: 15475955
CASR						Possibly increased: Increased, if there is chronic pancreatitis				Possibly increased: Hyperparathyroidism	Custom Order	PMID: 24624459; 30241646; 32386559; 7916660; 16497624; 18938753
CDC73			Non-cancerous/cancerous uterine tumors combined: > 50%						Renal tumors: ~13-15%	Hyperparathyroidism: up to 87% PMID: 25959515 Parathyroid cancer: ~15-23% PMID: 25959515, 31929790 Jaw tumors: ~30% PMID 31929790	Comprehensive (81 genes)	PMID: 31929790, 26450137
CDH1	Female: 41-60%						Female: 83% Male: 67%				GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Gastric Cancer V.1.2024
CDK4					Increased						Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 26892650
CDKN1B										Hyperparathyroidism & parathyroid tumors: ~80% Pituitary adenoma: ~37% Neuroendocrine tumor ~37% PMID: 28824003	Comprehensive (81 genes)	PMID: 28824003, 30990521
CDKN1C									Wilms tumor: 1.4%	Hepatoblastoma: Increased Adrenal cortical carcinoma: Increased Neuroblastoma: Increased Rhabdomyosarcoma: Increased PMID: 12138139	Comprehensive (81 genes)	PMID: 20301568, 16010495, 29377879
CDKN2A (p16INK4a)					28-76%	>15%					Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 16234564, 12072543, 26892650, 24935963, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.1.2023
CEBPA										Acute myeloid leukemia: Significantly increased PMID: 26162409	Comprehensive (81 genes)	PMID: 26162409, 20963938
CEP57 (biallelic)											Custom Order	PMID: 21552266
CFTR (biallelic)						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 21844754; 24624459; 27555793; 32172939; 9725921; 21520337
CFTR (monoallelic)						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 21844754; 24624459; 27555793; 32172939; 9725921; 21520337
CHEK2	Female: 20-40%			5-10%				Possibly increased			GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023
CHEK2 (p.I157T)	Female: <20%			5-10%				Possibly increased			GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023 PMID: 22799331, 37490054
CPA1						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 24624459; 23955596; 28258133
CTC1 (biallelic)										Possibly increased: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), squamous cell carcinoma of the head and neck or anogenital region	Custom Order	PMID: 20301779; 19282459
CTNNA1	Possibly increased						Possibly increased				Custom Order	PMID: 37686589; 37669414; 37165697; 36741258
CTR9									Possibly increased: Wilms tumor		Custom Order	PMID: 25099282
CTRC						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 24624459; 30241646
CYLD										Cylindroma, spiradenoma, or trichoepithelioma: Significantly increased PMID: 34744449 Salivary gland cancer: Increased Non-melanoma skin cancer: Increased PMID: 34744449, 32298062	Comprehensive (81 genes)	PMID: 34744449, 32298062
DDB2 (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
DDX41										Myeloid and lymphoid blood cancers: Increased PMID: 34723452, 34349893	Comprehensive (81 genes)	PMID: 34723452, 34349893
DICER1		Sex cord stromal tumors: Increased; onset in childhood							Benign kidney tumors: Increased; onset in childhood	Thyroid: Increased; onset in adulthood PMID: 29343557, 24761742 Pleuropulmonary blastoma: Increased; onset in childhood PMID: 29343557, 24761742	Comprehensive (81 genes)	PMID: 24761742, 29343557
DIS3L2 (biallelic)									Increased: Wilms tumor (> 32%)		Custom Order	PMID: 18780370; 34134020
DIS3L2 (monoallelic)											Custom Order	PMID: 18780370; 34134020
DKC1										Increased in males: acute myeloid leukemia, squamous cell carcinoma (SCC) of head and neck or anogenital region	Custom Order	PMID: 19282459; 20301779;
EGFR (T790M)										Lung: Increased, up to 31% PMID: 24736066	Comprehensive (81 genes)	PMID: 24736066, 34164592
EGLN1										Possibly increased: paraganglioma	Custom Order	PMID: 25263965; 19092153; 30877234
ENG				Possibly increased: Increased risk for polyposis, which may increase the risk for colorectal cancer							Custom Order	PMID: 16287957; 23399955
EPCAM		8-38%	21-57%	33-52%			0.2-9%	3.9- 23.8%	2.2- 28%	Biliary tract: 0.02%-1.7% PMID 21642682, 28754778 Brain/CNS: 2.5-7.7% PMID 28754778, 31337882, 18398828 Urothelial: 2.2-28% PMID 23091106, 21642682, 26657901, 31337882, 26385421, 18398828 Bladder: 4.4-12.8% PMID 21642682, 26657901, 31337882, 26385421 Small bowel: 1.1-10% PMID 21642682, 28754778, 31337882, 18398828	Lynch syndrome (5 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 20825397, 32534647
ERBB2	Possibly increased									Possibly increased: Lung	Custom Order	PMID: 26094658; 29752822; 31452768; 31477031; 19055823
ERCC1 (biallelic)					Possibly increased					Possibly increased: Basal cell carcinoma, squamous cell carcinoma, melanoma	Custom Order	PMID: 20301571
ERCC2 (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
ERCC3 (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
ERCC4 (biallelic)					Increased					Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
ERCC5 (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
EXT1										Osteochondromas: ~96% Chondrosarcoma: 2-5% PMID: 20301413, 8027127, 22258776, 25582066	Comprehensive (81 genes)	PMID: 20301413, 8027127, 22258776, 25582066
EXT2										Osteochondromas: ~96% Chondrosarcoma: 2-5% PMID: 20301413, 8027127, 22258776, 25582066	Comprehensive (81 genes)	PMID: 20301413, 8027127, 22258776, 25582066
EZH2										Possibly increased: Leukemia, lymphoma, neuroblastoma	Custom Order	PMID: 23865096; 31724824
FAN1				Possibly increased							Custom Order	PMID: 32449991; 26052075
FANCA (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCB (hemizygous)										Acute myeloid leukemia, squamous cell carcinomas Other solid tumors	Custom Order	PMID 20301575
FANCC (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCD2 (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCE (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCF (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCG (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCI (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCL (biallelic)										Myelodysplastic syndrome, acute myeloid leukemia, squamous cell carcinomas, Other solid tumors	Custom Order	PMID 20301575
FANCM (biallelic)											Custom Order	PMID 30075111; 29895858;
FBXW7									Possibly increased: Wilms tumor		Custom Order	PMID: 30885698
FH									10-19% (most commonly papillary RCC)	Paraganglioma and pheochromocytoma: increased in association with particular variants PMID: 12772087, 28300276	Comprehensive (81 genes)	PMID: 12772087, 28300276, 25012257, 20301430
FLCN				Possibly increased	Possibly increased				19-41% (includes multiple tumor types: chromophobe, clear cell, hybrid oncocytic, and papillary renal cancer)		Comprehensive (81 genes)	PMID: 20301695, 11927500, 22146830, 30586397, 30845233, 18234728, 26334087, 20522427, 20392993, 20413710, 19959076
GALNT12				5-10%							Multi-Cancer (40 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V2.2023
GATA1										Possibly increased: Osteogenic sarcoma, myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML)	Custom Order	PMID: 20301538; 35328001; 24453067; 20301769
GATA2										Myelodysplastic syndrome/acute myeloid leukemia: Increased \| PMID: 22691122	Comprehensive (81 genes)	PMID: 22691122, 25397911
GEN1								Possibly increased			Custom Order	PMID: 27433846
GNA11										Possibly increased: Hyperparathyroidism, hypocalciuria, hypercalcemia, hypocalcemia	Custom Order	PMID: 23802516; 26729423; 31672324 35679444
GPC3 (hemizygous)									Increased: Wilms tumor	Medulloblastoma, adrenal neuroblastoma, hepatoblastoma, hepatocellular carcinoma, gonadoblastoma	Custom Order	PMID: 20301398
GREM1				11-20% Increased risk for mixed polyposis (many polyps of different types)							Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 22561515
HNF1A									Possibly increased	Hepatocellular adenoma Possibly increased: hepatocellular carcinoma	Custom Order	PMID: 31166087, 12355088, 23707370, 31483937, 15649945
HNF1B									Possibly increased		Custom Order	PMID: 29792621, 15649945, 25536396, 21775974
HOXB13 (G84E)								33-60%			Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 26517352, 22841674, 25595936, 23457453, 29236593
HRAS										Rhabdomyosarcoma, neuroblastoma, bladder cancer (typically transitional cell carcinoma)	Custom Order	PMID: 20301680
KDM3B									Possibly increased: Wilms tumor		Custom Order	PMID: 20301471, 30885698
KIF1B										Possibly increased: Neuroblastoma, pheochromocytoma	Custom Order	PMID: 18334619; 24694336; 27986441; 32565791
KIT										Gastrointestinal stromal tumor (GIST): Increased PMID: 27437068	Comprehensive (81 genes)	PMID: 27437068
LZTR1 (biallelic)										Peripheral nerve schwannoma; spinal schwannoma; unilateral vestibular schwannoma: Increased PMID 29517885	Comprehensive (81 genes)	PMID: 29517885, 28620004, 27921248
LZTR1 (monoallelic)										Peripheral nerve schwannoma; spinal schwannoma; unilateral vestibular schwannoma: Increased PMID 29517885	Comprehensive (81 genes)	PMID: 29517885, 28620004, 27921248
MAX										Pheochromocytoma: Increased Paraganglioma: Possibly increased PMID: 28384794	Comprehensive (81 genes)	PMID: 28384794, 22452945, 20301715, 30536464
MBD4 one variant					Uveal (eye) melanoma: Increased						Custom Order	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023 PMID: 27911450; 35460607
MBD4 two variants				Uncertain cancer risk Increased risk for polyposis (many polyps)	Uveal (eye) melanoma: Increased					Acute myeloid leukemia (AML): Increased Schwannomas: Possibly increased	Custom Order	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023 PMID: 27911450; 35460607
MC1R					Possibly increased						Custom Order	PMID: 8894704; 24917043
MDM2											Custom Order	PMID: 17003841; 15550242
MEN1						Gastrinoma: 20-61% Functioning pancreatic neuroendocrine tumor: 20-80%	Gastric carcinoid tumors: 7-35%			Parathyroid tumors: 98% PMID: 22723327, 11739416 Pituitary adenomas: 35% PMID: 22723327, 11739416 Thymic carcinoid tumors: 10% PMID: 22723327, 11739416 Lung neuroendocrine carcinoid tumor: 10% PMID: 22723327, 11739416	Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.2.2020 PMID: 20301710, 11739416, 22723327
MET									Papillary RCC: Up to 100%; increased risk of bilateral/multifocal disease		Comprehensive (81 genes)	PMID: 15371818, 15285561, 30372385, 26637977, 33085428, 31801140, 33724750, 10433944
MITF (E318K)					Increased				Possibly increased		Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 22012259, 26488006, 22080950, 26892650, 26650189
MLH1		4-20%	34-54%	46-61%		6.20%	5-7%	4.4- 13.8%		Biliary tract: 1.9-3.7% PMID: 21642682, 28754778 Brain/CNS: 0.7-1.7% PMID: 27013479, 18398828 Renal pelvis and/or ureter: 0.2-5% PMID: 21642682, 28754778, 27013479, 26385421, 23091106 Bladder: 2-7% PMID: 28754778, 27013479, 26385421, 23091106 Small bowel: 0.4-11% PMID: 21642682, 23413378, 23091106	Lynch syndrome (5 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 20825397, 32534647
MLH3 (biallelic)				Possibly increased: colon polyposis, which may increase the risk for colorectal cancer							Custom Order	PMID: 30573798; 31043712
MRE11											Custom Order	PMID: 28418444; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024
MSH2		8-38%	21-57%	33-52%			0.2-9%	3.9- 23.8%	2.2- 28%	Biliary tract: 0.02%-1.7% PMID: 21642682, 28754778 Brain/CNS: 2.5-7.7% PMID: 28754778, 31337882, 18398828 Urothelial: 2.2-28% PMID: 21642682, 28754778, 31337882, 23091106, 26385421, 18398828 Bladder: 4.4-12.8% PMID: 28754778, 31337882, 23091106, 26385421 Small bowel: 1.1-10% PMID: 21642682, 28754778, 23091106, 18398828	Lynch syndrome (5 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 20825397, 32534647
MSH3 (biallelic)				Uncertain cancer risk Increased risk for polyposis (many polyps)							Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 35675019
MSH6		Up to 13%	16-49%	10-44%			Up to 7.9%		Up to 5.5%	Biliary tract: 0.2-PMID: 21642682, 28754778 Brain/CNS: 0.8-1.8% PMID: 20028993, 27013479, 28466842 Urothelial: 0.7-5.5% PMID: 21642682, 28754778, 27013479, 23091106, 26385421 Bladder: 1-8.2% PMID: 28754778, 27013479, 23091106, 26385421 Small bowel: PMID: 21642682, 23091106	Lynch syndrome (5 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 20825397, 32534647
MUTYH (biallelic)				70-90%						Duodenal: 4% PMID: 21171015, NCCN CRC	Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2023
NBN biallelic										Increased risk Lymphoma and solid tumors PMD: 22373003	GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 20301355, 22373003
NF1	Female: 20-40% (until age 50)									Peripheral nerve sheath tumors: Increased PMID: 19937438, 26926675, 16786042	GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.1.2023 PMID: 31010905, 2746095, 20301288
NF2										Vestibular schwannomas: Up to 100%, usually in both ears Spinal tumors : 66% Meningiomas: Up to 80% Astrocytoma: Possibly increased PMID: 20301380	Comprehensive (81 genes)	PMID: 20301380, 34464224, 15945431, 21278391, 16147576
NHP2 (biallelic)										Possibly increased: Acute myelogenous leukemia (AML), Squamous cell carcinoma of the head and neck or anogenital region	Custom Order	PMID: 18523010; 31985013
NOP10 (biallelic)										Possibly increased: Acute myelogenous leukemia (AML), Squamous cell carcinoma of the head and neck or anogenital region	Custom Order	PMID: 17507419
NTHL1 (biallelic)	Female: 6-56% by age 60		6-56% by age 60	>20% Increased risk for polyposis (many polyps)							Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2023
NYNRIN (biallelic)									Possibly increased: Wilms tumor		Custom Order	PMID: 30885698
PALB2	Female: 41-60% Male: 0.9%	3-5%				2-5%					GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024. PMID: 36827971, 25099575
PALLD						Possibly increased					Custom Order	PMID: 33764904; 30113427; 17194196
PARN (biallelic)										Possibly increased: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), squamous cell carcinoma of the head and neck or anogenital region	Custom Order	PMID: 20301779; 19282459; 25893599; 26810774
PARN (monoallelic)										Possibly increased: Lung cancer if there is pulmonary fibrosis	Custom Order	PMID: 20301779; 30285867
PAX5										Possibly increased: Acute lymphoblastic leukemia	Custom Order	PMID: 33036026; 24013638
PDGFRA										Gastrointestinal stromal tumor (GIST): PMID: Possibly increased \| 27437068	Comprehensive (81 genes)	PMID: 27437068
PHOX2B										Neuroblastoma: Up to 50% Ganglioneuroblastoma: <5% Ganglioneuroma: <5% PMID: 20301600	Comprehensive (81 genes)	PMID: 20301600, 28607627, 15338462
PIK3CA	Possibly increased		Possibly increased							Possibly increased: thyroid cancer	Custom Order	PMID: 23246288
PMS1	Possibly increased										Custom Order	PMID: 25151137; 29752822; 32029870
PMS2		1.3-3%	13-26%	8.7-20%			Unknown		Up to 3.7%	Biliary tract: 0.2- PMID: 28754778 Brain/CNS: 0.6-PMID: 30161022 Urothelial: PMID: 31337882	Lynch syndrome (5 genes) GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 20825397, 32534647
POLD1				>20% cancer risk Increased risk for polyposis (many polyps)							Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022
POLE				>20% cancer risk Increased risk for polyposis (many polyps)							Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022
POLH (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
POT1					Cutaneous melanoma: Increased					Chronic lymphocytic leukemia: Increased Angiosarcomas (cardiac and breast): Increased Glioma: Possibly increased PMID: 33119245	Comprehensive (81 genes)	PMID: 33119245, 28853721, 27528712
PRF1 (biallelic)											Custom Order	PMID: 20301617
PRKAR1A										Myxoma: up to 40% Primary pigmented nodular adrenocortical disease: 25% Large-cell calcifying Sertoli cell tumors: up to 41% Skin lesions: 30-80% Ovarian tumors: possibly increased PMID: 26130139, 25905341, 20301463	Comprehensive (81 genes)	PMID: 29372846, 28620449, 26130139, 30259502, 20301463, 15274075, 9351565, 32965923, 32809376, 25905341, 11095480
PRSS1						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 24624459; PMID: 30241646; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024
PTCH1										Basal cell carcinoma: up to 90% Medulloblastoma: 2% Cardiac fibroma: 2% Ovarian fibroma: 20% Jaw keratocysts: 90% PMID: 20301330	Comprehensive (81 genes)	PMID: 20301330, 27386043, 30725766, 32698852, 31778444, 28620006, 27386043, 8042673, 25403219
PTCH2										Possibly increased: Basal cell carcinoma, fibromas of the ovaries and heart, meningioma, medulloblastoma	Custom Order	PMID: 18285427; 31945512
PTEN	Female: 40->60%		28%	11-20%	6%				34%	Thyroid: 21-38% PMID: 17768394, 18972196, 22252256, 20565722	GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023
RAD50											Custom Order	PMID: 28418444; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024
RAD51C	Female: 17-30%	10-15%									GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Breast, Ovarian, and Pancreatic V.2.2024
RAD51D	Female: 17-30%	10-20%									GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024
RB1										Retinoblastoma: up to 90% (often bilateral) PMID: 29056300 Pinealoma (tumor in the pineal gland in the brain): Increased PMID 20301625 Osteosarcoma, Soft tissue sarcoma, Melanoma: Increased, especially if retinoblastoma was treated with radiation therapy PMID 20301625 Epithelial cancers (including lung and bladder): Increased PMID 20237571, 14996857	Comprehensive (81 genes)	PMID: 29056300, 20301625, 20237571, 14996857, 33801943
RECQL4 (biallelic)					Increased					Basal cell carcinoma, osteosarcoma, lymphoma, squamous cell carcinoma	Custom Order	PMID: 20301415; 20301383
REST									Increased: Wilms tumor		Custom Order	PMID: 26551668, 32412586, 30885698
RET										Subtype: [MEN2A] Medullary thyroid cancer: 95% Pheochromocytoma: 50% Parathyroid disease: 20-30% [FMTC] Medullary thyroid cancer: 100% [MEN2B] Medullary thyroid cancer: 100% Pheochromocytoma: 50% Parathyroid disease: rare PMID: 31390501	Comprehensive (81 genes)	PMID: 20301434, 31390501, 25810047
RHBDF2										Esophageal: Up to 95% (based on a small number of known affected families) PMID: 18559331	Comprehensive (81 genes)	PMID: 18559331, 26419362, 28723042
RINT1											Custom Order	PMID: 27544226; 33471991
RNF43				Possibly increased: Increased risk for serrated polyposis, which may increase the risk for colorectal cancer							Multi-Cancer (40 genes)	PMID: 24512911; 27081527; 27329244; 29330307; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V2.2023
RPL11				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL15				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL18				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL19										Possibly increased: myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 22431104; 30503522
RPL26				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL27				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL35				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL35A				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPL5				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS10				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS15A				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS17				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS19				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS20				Possibly increased							Multi-Cancer (40 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V2.2023
RPS24				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS26				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS27				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS28				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS29				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RPS7				Increased						Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
RTEL1										Myelodysplastic syndrome (MDS) and myeloid leukemia, solid tumors most often SCC (head and neck, anal & genital)	Custom Order	PMID 20301779
RUNX1										Myelodysplastic syndrome/acute myeloid leukemia: 20-50% PMID: 33661592	Comprehensive (81 genes)	PMID: 33661592, 18723428, 19357396
SAMD9L										Myelodysplastic syndrome (MDS) and myeloid leukemia	Custom Order	PMID 28570036
SDHA									Increased	Gastrointestinal stromal tumor (GIST): Increased Thyroid: Increased Paraganglioma/Pheochromocytoma: Increased PMID: 20301715	Comprehensive (81 genes)	PMID: 20301715
SDHAF2										Gastrointestinal stromal tumor (GIST): Possibly increased Paraganglioma: Increased; Pheochromocytoma: Possibly increased PMID: 31390501, 21224366	Comprehensive (81 genes)	PMID: 20301715, 31390501, 33081307, 21224366, 30536464
SDHB									Increased	Gastrointestinal stromal tumor (GIST): Increased Thyroid: Increased Paraganglioma/Pheochromocytoma: Increased PMID: 20301715	Comprehensive (81 genes)	PMID: 20301715
SDHC									Increased	Gastrointestinal stromal tumor (GIST): Increased Thyroid: Increased Paraganglioma/Pheochromocytoma: Increased PMID: 20301715	Comprehensive (81 genes)	PMID: 20301715
SDHD									Increased	Gastrointestinal stromal tumor (GIST): Increased PMID: 20301715 Thyroid: Increased Paraganglioma/Pheochromocytoma: Increased PMID: 20301715	Comprehensive (81 genes)	PMID: 20301715
SLC45A2 (biallelic)					Possibly increased					Other skin cancers (BCC and SCC)	Custom Order	PMID 20301683
SLC45A2 (monoallelic)					Possibly increased						Custom Order	PMID 28192564; 20301683
SLX4 (biallelic)										Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), squamous cell carcinomas, other solid tumors	Custom Order	PMID 20301575
SLX4 (monoallelic)	Possible										Custom Order	PMID 30306255; 28202063; 22911665; 23211700; 23840564; 24733792
SMAD4				Up to 50%			Up to 21%			Small bowel: Rare, currently undefined PMID: 25645574	Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.1.2022 PMID: 19553198
SMARCA4		Small cell carcinoma of hypercalcemic type: Possibly increased								Rhabdoid tumors: Possibly increased (preliminary evidence) PMID: 25886974, 27866340, 20137775, 25060813	Comprehensive (81 genes)	PMID: 25886974, 29215836
SMARCB1										[Rhabdoid tumor predisposition syndrome]: Rhabdoid tumor of the kidney, central nervous system, and/or other organs: Increased; Schwannoma: Possibly increased PMID: 29215836, 33692948, 28620006 [Schwannomatosis]: Schwannoma: Increased; Meningioma: Mildly increased; Malignant schwannoma: Possibly increased PMID: 29215836, 33692948, 28620006	Comprehensive (81 genes)	PMID: 29215836, 29517885, 33692948, 28620006
SMARCE1										Meningioma: Increased PMID: 29215836, 26803492, 27891692, 27264197	Comprehensive (81 genes)	PMID: 26803492, 27891692, 27264197
SPINK1						Possibly increased: Increased, if there is chronic pancreatitis					Custom Order	PMID: 24624459; 30241646; 10835640; 14722925; 27578509; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024
SPRED1										Possibly increased: leukemia	Custom Order	PMID 20945555
SRP72										Possibly increased: myelodysplastic syndrome (MDS)	Custom Order	PMID: 22541560
STK11	Female: 32-54%	Sex cord tumors with annular tubules or SCTAT: At least 20%	9%	39%		11-36%	29%			Small bowel: 13% PMID: 16707622, 11113065 Lung: 7-17% PMID: 16707622, 11113065 Testicular tumors: 9% PMID: 16707622 Cervical adenoma malignum: 10% PMID: 16707622	GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023
SUFU										Basal cell carcinoma: Up to 90% Medulloblastoma: Up to 33% Cardiac fibroma: 2% Ovarian fibroma: Increased PMID: 20301330	Comprehensive (81 genes)	PMID: 20301330, 28620006, 21834049, 33024317, 28965847
TERC										Acute myeloid leukemia: Increased; squamous cell carcinoma of head and neck: Increased; anal and genital cancer: Increased PMID: 20301779	Comprehensive (81 genes)	PMID: 20301779, 33808277
TERT (biallelic)										Acute myeloid leukemia; squamous cell carcinoma of head and neck; anal cancer; genital cancer: Increased PMID: 20301779	Comprehensive (81 genes)	PMID: 20301779, 19282459, 33808277
TERT (monoallelic)										Acute myeloid leukemia; squamous cell carcinoma of head and neck; anal cancer; genital cancer: Increased PMID: 20301779	Comprehensive (81 genes)	PMID: 20301779, 19282459, 33808277
TINF2										Acute myeloid leukemia (AML), solid tumors most often SCC (head and neck, anal & genital)	Custom Order	PMID 20301779
TMEM127									Possibly Increased	Gastrointestinal stromal tumor (GIST): Possibly increased PMID: 24334765, 31390501, 21613359 Pheochromocytoma/Paraganglioma: Increased PMID: 31390501, 21613359	Comprehensive (81 genes)	PMID: 24334765, 20301715, 31390501, 21613359
TP53	Female: >60%			>20%		5%				Sarcoma: Increased PMID 27496084, 1933872, 20301488 Brain/CNS: Increased PMID 27496084, 1933872, 20301488 Adrenocortical carcinoma: increased PMID 27496084, 1933872, 20301488 Leukemia: Risk not well established PMID 27496084, 23334668, 24706533,20301488	GYN guidelines-based (19 genes) Multi-Cancer (40 genes) Comprehensive (81 genes)	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian and Pancreatic V.3.2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Colorectal V.2.2023 PMID: 34709361, 36827971, 31069009, 29977421
TRIM28									Increased: Wilms tumor		Custom Order	PMID: 20301471; 30885698; 29912901; 30694527; 33565090; 32412586
TRIP13 (biallelic)									Possibly increased: Wilms tumor		Custom Order	PMID 28553959
TSC1									Kidney cancer: 2-5% Kidney tumors: Increased	Brain/CNS: Increased PMID: 20301399 Lung (lymphangioleiomyomatosis): Increased in females PMID: 20301399 Cardiac rhabdomyomas: Increased PMID: 20301399	Comprehensive (81 genes)	PMID: 20301399
TSC2									Kidney cancer: 2-5% Kidney tumors: Increased	Brain/CNS: Increased PMID: 20301399 Lung (lymphangioleiomyomatosis): Increased in females PMID: 20301399 Cardiac rhabdomyomas: Increased PMID: 20301399	Comprehensive (81 genes)	PMID: 20301399
TSR2 (hemizygous)				Possibly increased						Possibly increased: Lung cancer, cervical cancer, myelodysplastic syndrome, acute myelogenous leukemia, osteogenic sarcoma	Custom Order	PMID 20301769; 29051281
TYR (biallelic)					Possibly increased					Skin cancer (BCC & SCC)	Custom Order	PMID 37053367
TYR (monoallelic)					Possibly increased					Possibly increased: other skin cancer (BCC & SCC)	Custom Order	PMID 29036293; 31233279
USB1 (biallelic)										Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), skin cancer (squamous cell carcinoma)	Custom Order	PMID 29072891
VHL						Pancreatic Neuroendocrine tumor: ~5-17%			~70% by age 60	CNS Hemangioblastoma: 60-80% PMID: 20301636 Pheochromocytoma: 10-20% PMID: 20301636 Endolymphatic sac tumor: 10-16% PMID: 20301636	Multi-Cancer (40 genes) Comprehensive (81 genes)	PMID: 20301636
WRAP53 (biallelic)										Possibly increased: Squamous cell carcinoma of the head and neck or anogenital region, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML)	Custom Order	PMID: 20301779; 19282459
WRN (biallelic)					Increased					Thyroid, soft-tissue sarcoma, osteosarcoma Possibly increased: Meningioma, leukemia	Custom Order	PMID: 20301687; 23573208; 24356923; 26993153
WT1									Wilms tumor: Increased	Gonadoblastoma: Increased PMID: 32352694, 34134020	Comprehensive (81 genes)	PMID: 32352694, 34134020
XPA (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
XPC (biallelic)					Increased					Basal cell carcinoma, squamous cell carcinoma, eye cancer	Custom Order	PMID 20301571
XRCC2	Possibly increased										Custom Order	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2024